Latest ExpreS2ion Biotechnologies News & Updates

See the latest news and media coverage for ExpreS2ion Biotechnologies. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
ExpreS2ion Biotechnologies

Clinical-stage vaccine biotechnology company

expres2ionbio.com
Headquarters
Horsholm, Denmark
Founded year
2010
Company type
Public company
Number of employees
20–50

Latest news about ExpreS2ion Biotechnologies

Company announcements

  • ExpreS2ion Biotechnologies

    ExpreS2ion Biotechnologies advances ES2B-C001 through phase I

    Interim data expected over summer; phase I completion targets end of 2026. Rights issue remains open until April 30. Platform develops via partnerships.

  • ExpreS2ion Biotechnologies

    ExpreS2ion highlights BIO-002 clinical data validating platform

    Phase Ia study shows favorable safety, consistent antibody responses, and scalable dosing for malaria vaccine antigen produced with ExpreS2 platform. Supports partnered model and oncology pipeline.

  • ExpreS2ion Biotechnologies

    ExpreS2ion Biotechnologies announces rights issue and clinical progress

    CEO discusses Phase I advancement of ES2B-C001 in breast cancer, pipeline updates, and partnerships in interview. Proceeds fund development.

  • ExpreS2ion Biotechnologies

    ExpreS2ion publishes prospectus for SEK 53 million rights issue

    The issue supports Phase I completion for ES2B-C001 anti-HER2 therapy, partnering, and manufacturing. Subscription period runs from 16-30 April 2026.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about ExpreS2ion Biotechnologies

Track ExpreS2ion Biotechnologies and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

ExpreS2ion Biotechnologies competitors & trending companies

Browse news for competitors to ExpreS2ion Biotechnologies and other trending companies.